Form 8-K - Current report:
SEC Accession No. 0001171843-25-003935
Filing Date
2025-06-17
Accepted
2025-06-17 08:00:40
Documents
13
Period of Report
2025-06-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f6k_061725.htm   iXBRL 8-K 20579
2 EXHIBIT 99.1 exh_991.htm EX-99.1 6640
  Complete submission text file 0001171843-25-003935.txt   194066

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE apto-20250617.xsd EX-101.SCH 3029
4 XBRL LABEL FILE apto-20250617_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE apto-20250617_pre.xml EX-101.PRE 22368
15 EXTRACTED XBRL INSTANCE DOCUMENT f6k_061725_htm.xml XML 3597
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 251051853
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)